GlassScriptPhysician profile
Xiaojun X Yan
NPI 1033110788
$249,375.89
in general payments reported to CMS, 2019-2025
32 companies · $16K in 2025
The $16K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $26K · 2021: $45K · 2022: $54K · 2023: $43K · 2024: $32K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $9,782 · Consulting Fee: $4,533 · Travel and Lodging: $454 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,892.00 |
| Food and Beverage | $9,781.64 |
| Consulting Fee | $4,532.50 |
| Travel and Lodging | $453.55 |
| Education | $187.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $110,822.57 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $63,875.94 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47,848.77 | 2019-2025 | Spiriva, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $12,598.67 | 2019-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $7,901.91 | 2019-2021 | |
| Genzyme Corporation | $1,141.94 | 2019-2025 | |
| Genentech USA, INC. | $750.92 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $651.71 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $540.94 | 2019-2024 | Yupelri |
| Philips North America LLC | $501.49 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Actelion Pharmaceuticals US, INC. | $454.63 | 2022-2025 | Opsumit, Uptravi |
| Regeneron Pharmaceuticals, INC. | $360.66 | 2019-2021 | |
| Advanced Respiratory, INC | $307.74 | 2019-2021 | |
| Grifols USA, LLC | $263.14 | 2019-2025 | Prolastin-C Liquid |
| Inogen, INC. | $255.64 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $178.45 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $156.06 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $121.12 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $88.36 | 2023 | Nuzyra |
| Amgen INC. | $88.14 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $80.80 | 2020-2022 | |
| Electromed, INC. | $71.65 | 2022-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $60.03 | 2021-2022 | |
| Pfizer INC. | $52.21 | 2022-2024 | |
| Optinose US, INC. | $45.41 | 2020-2021 | |
| Circassia INC. | $28.34 | 2021 | |
| Viatris Specialty LLC | $27.57 | 2025 | Yupelri |
| Verona Pharma, INC. | $25.00 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $22.42 | 2021 | |
| Horizon Therapeutics Plc | $18.49 | 2020 | |
| United Therapeutics Corporation | $17.59 | 2021 | |
| Hikma Pharmaceuticals USA | $17.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaojun Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.